HK Stock Market Move | SINOMAB BIO-B (03681) rises by over 5% again, highlighting the strong potential for treating CRSwNP and IPF in SM17 preclinical studies.

Sinomab Bio-B (03681) surged over 5%, as of press time, rising by 4.62% to 2.04 Hong Kong dollars, with a turnover of 13.36 million Hong Kong dollars. On the news front, Sinomab Bio announced that its novel anti-IL-17RB antibody SM17's preclinical research has been published in the "European Respiratory Journal - Open Research." The study showed that SM17 significantly improved the pathological characteristics of chronic rhinosinusitis with nasal polyps (CRSwNP) and idiopathic pulmonary fibrosis (IPF) by dual inhibition of Th2/Th17 pathways and anti-fibrotic activity, supporting its potential as a transformative therapy. Chairman, Executive Director, and CEO of Sinomab Bio, Liang Ruian, expressed his delight at the publication of the preclinical research on SM17 in the "European Respiratory Journal - Open Research," highlighting its potential in treating CRSwNP and IPF. The results suggest that SM17 is a promising potential novel biologic targeting the key upstream alarmist (IL-25). By simultaneously targeting Th2 inflammation, Th17 differentiation, and fibrosis, SM17 may provide a multifaceted treatment strategy for CRSwNP and IPF, addressing the unmet needs of limitations in current downstream effector targeted therapies.